A recent review examined a sequential eradication strategy that uses specific herbal compounds to treat disease. The proposed method involves three steps: barrier disruption using epigallocatechin gallate and baicalin, metabolic resuscitation with Astragalus polysaccharides, and terminal eradication using berberine and shikonin. These components are designed to work through microenvironment-responsive delivery systems.
The study did not report specific patient numbers or safety data because it was a review of existing information rather than a new clinical trial. No adverse events or discontinuations were listed in the available evidence.
The main takeaway is that while the theoretical approach is detailed, moving it into real-world clinical practice is difficult. Experts note that manufacturing and regulatory complexities currently prevent these multi-component therapies from being used safely and effectively in hospitals or clinics.
Readers should understand that this information describes a complex concept rather than a ready-to-use treatment. Until manufacturing and regulatory hurdles are cleared, these herbal combinations cannot be recommended for patient care.
